Apimeds Pharmaceuticals US

APUS

Market cap $20.6M

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and.

MATAWAN, N.J.--(BUSINESS WIRE)--(NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (“Apimeds”), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that it has merged with MindWave Innovations Inc (“MindWave”; the transaction, the “Merger”). Today, Apimeds and MindWave signed the merger agreement (the “Merger Agreement”) outlining the terms of the Merger, thus paving the way for a dual-growth enterprise spanning advanced biotechnology and institutional.

MATAWAN, N.J. & MOSCOW, Idaho--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the he.

MATAWAN, N.J. & EUGENE, Ore.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon's Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the health.

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego's Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Future Labs is part of Apimeds' ai² innovation.

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company's lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled “Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry”, can be found here: https://www.fda.gov/regulatory-inform.

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Future Labs is part of Apimeds' ai² innovation platform, connectin.

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Dr. Kramer brings more than 30 year.

Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The shares began trading on the NYSE American on May 9, 2025, under the symbol “APUS.”

A few new issuers went public this past week, joined by two SPACs. Three IPOs are scheduled to list in the week ahead, although some small deals may join the calendar at the last minute. Street research is expected for three companies in the week ahead, and one lock-up period will be expiring.